ESMO - Eur. Oncology
@myESMO
Followers
81K
Following
31K
Media
6K
Statuses
20K
The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
Lugano - Switzerland
Joined August 2009
@ModestDominik discusses precision medicine in #colorectal cancer treatment at #ESMOAsia25 @myESMO @LizzySmyth1
0
1
1
Excellent commentary @Ecastromarcos at #ESMOAsia25 putting three prostate cancer abstracts into clinical context—highlighting how genomic tools, AI pathology, and targeted therapies are reshaping risk stratification and treatment intensification across the disease continuum
0
2
7
Kicking off activities at @myESMO #ESMOAsia25 with a short talk on #AI_drivenBiomarkers and what are the #potentials and #implications of these in #drugdevelopment and #oncologyclinicalcare. 📢 A shoutout to the just released #EBAI guidance document: check it out here:
0
4
17
#ESMOAsia2025🔥 Investigator-initiated 1L Ph II/III trial Crizotinib+Chemo v Criz in ALK+ NSCLC @TataMemorial - study stopped early - DCR 55% v 75% in favour of Criz - 11SAEs 8 deaths- sepsis main tox A cautionary tale- more is not always more #ESMOAmbassadors @myESMO #LCSM
0
4
22
Consider joining @esmo as a member at #ESMOAsia25 with this amazing deal and be part of a 50k strong membership family! @myESMO
0
3
5
A huge opportunity to join a global community @ravikanesvaran @myESMO
Consider joining @esmo as a member at #ESMOAsia25 with this amazing deal and be part of a 50k strong membership family! @myESMO
0
3
10
Patient-reported data are essential to understanding real gaps in cancer care. IKCC GPS 2025 shows that SDM remains limited across Asia and up to 92% of kidney cancer patients face treatment barriers. Listening to patients must guide action. #ESMOAsia25 @IKCCorg #PatientVoice
0
3
3
Excellent discussion in the GU Mini Oral session this morning #ESMOAsia25 thoughtfully putting new data into clinical context and highlighting what it means for real-world practice across Asia. Great insights from Dr Senthil Rajappa @myESMO
0
3
3
Proffered Paper in #BTC at @myESMO #ESMOAsia25
#TOURMALINE (DurvaChemo nonTOPAZ) in #Asia (90 pts) iCCA51%; GBC30%; PS2 16.7% 52% G3-4 AEs – haem/cholangitis; 13% anyG imAE; 6.7% IRR 26.7% ORR – best CisGem (PS2; ORR 50%) 📝Confirms data in Asia 👯♀️Doublet (vs mono) chemo best
0
3
2
A global oncology society. Great benefits for our members. Join the strong 50k family! #ESMOAsia25 @myESMO #ESMO25
https://t.co/YedCCMb0CW
Consider joining @esmo as a member at #ESMOAsia25 with this amazing deal and be part of a 50k strong membership family! @myESMO
0
0
4
🚨My take home message from #TOURMALINE at @myESMO #ESMOAsia25 👎Gem-alone underperforms vs doublet (agreed #DrChan) BUT… 🥳CisGemDurva in #PS2 from #Global population (n=18) SIMILAR to #TOPAZ (📸3-4) @GrupoTTD @atuvibi @CharityAMMF @curecc @enscca @myESMO #ESMOAsia25
Proffered Paper in #BTC at @myESMO #ESMOAsia25
#TOURMALINE (DurvaChemo nonTOPAZ) in #Asia (90 pts) iCCA51%; GBC30%; PS2 16.7% 52% G3-4 AEs – haem/cholangitis; 13% anyG imAE; 6.7% IRR 26.7% ORR – best CisGem (PS2; ORR 50%) 📝Confirms data in Asia 👯♀️Doublet (vs mono) chemo best
0
3
5
Meet the expert: ESMO GI Oncology Journal in Asia. #SuPinChoo moderates #FlorianLordick discussing #gastric cancer and #claudin 18.2 in Asia at #ESMOAsia25 in Singapore @myESMO
0
1
4
Super engaged #ESMOYOC session of #ESMOAsia25 with Vesalius talk about Research, Education, & Collaboration for #YoungOncologists in Asia-Pacific, fantastic discussion with our amazing international experts 🤩 @devnani_bharti 🇮🇳 @MarianaBrandao0 🇧🇪 #StephanChan 🇭🇰 @oncopigmd 🇵🇭
0
2
4
@LizzySmyth1 and #Nai-Jung Chiang chairing the session on integrating of novel biomarkers in the treatment of #GI tumors at #ESMOAsia25 @myESMO
0
1
2
@changhoon_yoo discusses biomarker-based approaches in hepatobiliary and pancreatic cancer #HCC #BTC #CCA #PDAC at #ESMOAsia25 @myESMO @LizzySmyth1
0
2
2
⏰ Countdown alert! Abstracts for ESMO Sarcoma and Rare Cancers 2026 are due 9 December. 👉 As the Co-Chairs highlight, your work can drive rare cancer research forward, boost collaboration & shape public health. Don’t miss your chance! #ESMORareCancers26 #esmomeetings 🔗
0
1
2
#ESMOAsia25: Encouraging phase II findings were presented with the p53 reactivator, rezatapopt, in patients with heavily pre-treated solid tumours expressing the TP53 Y220C mutation. 📌Read more: https://t.co/5EChFH3by8
#ESMODailyReporter
0
5
8
ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the exceptional scientific merit of their abstracts. #ESMOAsia25 👉 https://t.co/0WT9iejqAC
0
3
7